Jazz sells priority review voucher for $200M, scoring highest price in a decade
爵士制药以2亿美元出售优先审评凭证，创下近十年来最高价格

Jazz Pharmaceuticals said it sold a priority review voucher to an undisclosed company for $200 million, landing the highest price for such a voucher since 2016.
爵士制药表示已将一张优先审评券以2亿美元的价格出售给一家未披露名称的公司，创下自2016年以来此类券的最高成交价。